A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas

Miso Kim; Jeong-Ok Lee; Jiwon Koh; Tae Min Kim; Ji Yun Lee; Yoon Kyung Jeon; Bhumsuk Keam; Dong-Wan Kim; Jong Seok Lee; Dae Seog Heo

doi:10.3324/haematol.2021.278301

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas

Haematologica. 2021 Aug 1;106(8):2277-2280. doi: 10.3324/haematol.2021.278301.

Authors

Affiliations

¹ Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Cancer Research Institute, Seoul.
² Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam.
³ Department of Pathology, Seoul National University Hospital, Seoul.
⁴ Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Cancer Research Institute, Seoul. gabriel9@snu.ac.kr.
⁵ Seoul National University Cancer Research Institute, Seoul, Republic of Korea; Department of Pathology, Seoul National University Hospital, Seoul.

No abstract available

Publication types

Clinical Trial, Phase II
Research Support, Non-U.S. Gov't

MeSH terms

Brentuximab Vedotin
Epstein-Barr Virus Infections* / complications
Epstein-Barr Virus Infections* / drug therapy
Herpesvirus 4, Human
Humans
Immunoconjugates* / therapeutic use
Ki-1 Antigen
Lymphoma*

Substances

Immunoconjugates
Ki-1 Antigen
Brentuximab Vedotin

Associated data

ClinicalTrials.gov/NCT02388490

Grants and funding

Funding: this study was funded by Takeda Pharmaceuticals Co, Ltd. and supported by a grant from the Korean Health Technology R&D Project "Strategic Center of Cell and Bio Therapy for Heart, Diabetes & Cancer” through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare (MHW) (grant number: HI-17C-2085).